2016
DOI: 10.1021/acsmedchemlett.6b00184
|View full text |Cite
|
Sign up to set email alerts
|

Development of N-(4-Phenoxyphenyl)benzenesulfonamide Derivatives as Novel Nonsteroidal Progesterone Receptor Antagonists

Abstract: ABSTRACT:We report here development of N-(4-phenoxyphenyl)benzenesulfonamide derivatives as a novel class of nonsteroidal progesterone receptor (PR) antagonists. PR plays key roles in various physiological systems, including the female reproductive system, and PR antagonists are candidates for clinical treatment of multiple diseases, including uterine leiomyoma, endometriosis, breast cancer, and some psychiatric disorders. We found that the benzenesulfonanilide skeleton functions as a novel scaffold for PR ant… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
14
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
2
1

Relationship

3
6

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 36 publications
(48 reference statements)
0
14
0
Order By: Relevance
“…13) However, all PR ligands in clinical use, including 2, possess a steroidal structure, which may cause significant adverse effects due to cross-activity with other steroid hormone receptors. 14) To avoid these adverse effects, several non-steroidal PR ligands have been developed, such as tanaproget (3) 15) and sulfonamide derivative 4 16) (Fig. 1).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…13) However, all PR ligands in clinical use, including 2, possess a steroidal structure, which may cause significant adverse effects due to cross-activity with other steroid hormone receptors. 14) To avoid these adverse effects, several non-steroidal PR ligands have been developed, such as tanaproget (3) 15) and sulfonamide derivative 4 16) (Fig. 1).…”
Section: Introductionmentioning
confidence: 99%
“…In the case of 3, X-ray crystallographic analysis of the complex of 3 with the PR-LBD revealed that the cyano group of 3 interacts with Gln725 and Arg766 of PR-LBD, which are the same amino acid residues that interact with the 3-carbonyl group of 1. 15) In the previous study, we developed non-steroidal PR antagonists bearing a boron-cluster carborane as the hydrophobic core structure. [17][18][19][20] Carboranes, or more precisely dicarbacloso-dodecaboranes (C 2 B 10 H 12 ), are carbon-containing boron clusters with an icosahedral cage structure, and there are three isomers, depending on the positions of the two carbon atoms, that is, ortho-, meta-, and para-carborane.…”
Section: Introductionmentioning
confidence: 99%
“…[17][18][19] In addition to these tanaproget derivatives, nonsteroidal PR antagonists with novel chemotypes distinct from tanaproget (2) have been also investigated. For example, 3-aryl indole derivatives including 6 were developed as PR antagonists to treat uterine fibroids, 20) and other structures such as 7 and 8 have also been reported in recent years [21][22][23][24] (Fig. 1).…”
Section: Introductionmentioning
confidence: 99%
“…15,16) However, all PR ligands currently in clinical use, including 2, are steroid derivatives, and may have significant adverse effects because of their cross-activity toward other steroid hormone receptors. 17) In order to avoid these adverse effects, non-steroidal PR ligands are required, and indeed, several non-steroidal ligands have been developed, such as tanaproget (3) 18) and a sulfonamide derivative (4) 19) (Fig. 1).…”
mentioning
confidence: 99%